ReviewFrontiers in cellular and infection microbiology2022
Therapeutic Antibodies Against Shiga Toxins: Trends and Perspectives.
Review in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Recombinant Human Fab Antibodies Differentially Neutralize Shiga Toxin in Renal Epithelial and Endothelial Cells.Toxins · 2026Article
- Antibody Screening and Binding Prediction Analysis Targeting Stx2.Antibodies (Basel, Switzerland) · 2026Article
- Next-generation anti-infective drugs in the post-antibiotic era: focusing on anti-virulence agents targeting the bacterial quorum sensing system.Frontiers in cellular and infection microbiology · 2026Review
- Engineered Mycoplasma pneumoniae targeting dual-species bacterial biofilms: a novel strategy against infections.NPJ biofilms and microbiomes · 2025Article
- In Silico Design of a Multiepitope Vaccine Against Intestinal PathogenicDiseases (Basel, Switzerland) · 2025Article
- Mechanisms of antibody-dependent enhancement of infectious disease.Nature reviews. Immunology · 2025Review
- From Bench to Body: ProtectiveJournal of cellular immunology · 2025Article
- Shiga Toxins Produced by EnterohaemorrhagicJournal of microbiology and biotechnology · 2024Article
- Isolation and Characterization of NovelBiomedicines · 2024Article
- What is the role of microbial biotechnology and genetic engineering in medicine?MicrobiologyOpen · 2024Review
- Article
- A novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy.Antimicrobial agents and chemotherapy · 2024Article
- Characterization of the novel temperate Escherichia coli phage phiStx2k.Archives of virology · 2023Article
- Enzymatic Cleavage of Stx2a in the Gut and Identification of Pancreatic Elastase and Trypsin as Possible Main Cleavers.Microorganisms · 2023Article
- Diagnosis and Treatment for Shiga Toxin-ProducingToxins · 2022Review
- Antibody-Based Immunotherapies as a Tool for Tackling Multidrug-Resistant Bacterial Infections.Vaccines · 2022Review
- O55 Polysaccharides Are Good Antigen Targets for the Formulation of Vaccines against O55 STEC and Capsulated aEPEC Strains.Pathogens (Basel, Switzerland) · 2022Article
- SARS-CoV-2 and Emerging Foodborne Pathogens: Intriguing Commonalities and Obvious Differences.Pathogens (Basel, Switzerland) · 2022Review
- EnterohemorrhagicInternational journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Shiga toxins (Stx) are AB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.